DK1298208T3 - Ribozymer der er målrettet mod en HIV-tat-sekvens - Google Patents

Ribozymer der er målrettet mod en HIV-tat-sekvens

Info

Publication number
DK1298208T3
DK1298208T3 DK02025406T DK02025406T DK1298208T3 DK 1298208 T3 DK1298208 T3 DK 1298208T3 DK 02025406 T DK02025406 T DK 02025406T DK 02025406 T DK02025406 T DK 02025406T DK 1298208 T3 DK1298208 T3 DK 1298208T3
Authority
DK
Denmark
Prior art keywords
compound
hiv
hiv tat
tat sequence
ribozymes targeting
Prior art date
Application number
DK02025406T
Other languages
English (en)
Inventor
Geoffrey P Symonds
Lun-Quan Sun
Original Assignee
Gene Shears Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/178,082 external-priority patent/US5712384A/en
Application filed by Gene Shears Pty Ltd filed Critical Gene Shears Pty Ltd
Application granted granted Critical
Publication of DK1298208T3 publication Critical patent/DK1298208T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK02025406T 1994-01-05 1995-01-05 Ribozymer der er målrettet mod en HIV-tat-sekvens DK1298208T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/178,082 US5712384A (en) 1994-01-05 1994-01-05 Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
US08/310,259 US6114167A (en) 1994-01-05 1994-09-21 Ribozymes targeting the MoMLV PSI packaging sequence and the HIV tat sequence
EP95905220A EP0753062A4 (en) 1994-01-05 1995-01-05 RIBOZYMES TARGETING RECOMBINATION PRODUCTS OF EXPRESSION OF RETROVIRAL PACKAGING SEQUENCES AND RECOMBINANT RETROVIRUSES CONTAINING SAID RECOMBINATION PRODUCTS

Publications (1)

Publication Number Publication Date
DK1298208T3 true DK1298208T3 (da) 2006-07-24

Family

ID=26873946

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02025406T DK1298208T3 (da) 1994-01-05 1995-01-05 Ribozymer der er målrettet mod en HIV-tat-sekvens

Country Status (14)

Country Link
EP (2) EP1298208B1 (da)
JP (1) JP3691849B2 (da)
CN (1) CN1267552C (da)
AT (1) ATE320487T1 (da)
AU (1) AU698730B2 (da)
CA (1) CA2180358A1 (da)
DE (1) DE69534864T2 (da)
DK (1) DK1298208T3 (da)
ES (1) ES2260376T3 (da)
IL (1) IL112261A (da)
NO (1) NO319376B1 (da)
NZ (1) NZ278432A (da)
PT (1) PT1298208E (da)
WO (1) WO1995018854A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020058636A1 (en) * 1994-09-21 2002-05-16 Geoffrey P. Symonds Ribozymes targeting the retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs
EP0865282A4 (en) * 1995-08-25 2002-01-16 Univ California Chimeric antiviral agents that contain REV-binding nucleic acids
NZ324157A (en) * 1995-11-28 2000-10-27 Univ Johns Hopkins Med Conditionally replicating viral vectors and their use in treating HIV
US5888767A (en) 1996-11-27 1999-03-30 The Johns Hopkins University School Of Medicine Method of using a conditionally replicating viral vector to express a gene
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
NZ547283A (en) 1998-03-20 2008-06-30 Commw Scient Ind Res Org Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE60238486D1 (de) 2001-07-10 2011-01-13 Johnson & Johnson Res Pty Ltd Verfahren zur genetischen modifikation hämatopoetischer vorläuferzellen und verwendungen der modifizierten zellen
US7994144B2 (en) 2001-07-10 2011-08-09 Johnson & Johnson Research Pty, Limited Process for the preparation of a composition of genetically modified hematopoietic progenitor cells
CN102841007A (zh) * 2012-09-05 2012-12-26 福建省农业科学院畜牧兽医研究所 一种便于鸭精子计数的精液稀释液及其使用方法
CN113549641B (zh) * 2021-06-29 2023-12-22 复旦大学 一种核酶介导的多顺反子载体及其构建方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225337A (en) * 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Ribozyme compositions and methods for use
JPH06506599A (ja) * 1991-04-05 1994-07-28 エディソン　アニマル　バイオテクノロジー　センター，オハイオ　ユニバーシティー パッケージング配列に相補的なアンチセンス核酸によるレトロウイルスの抑制
CA2154363A1 (en) * 1993-01-22 1994-08-04 Bruce A. Sullenger Localization of therapeutic agents
IL108719A0 (en) * 1993-02-25 1994-08-26 Ortho Pharma Corp Expression constructs containing hiv inhibitory antisense and other nucleotide sequences, retroviralvectors and recombinant retroviruses containing them
WO1995004818A1 (en) * 1993-08-06 1995-02-16 Ribozyme Pharmaceuticals, Inc. Method and reagent for inhibiting human immunodeficiency virus replication

Also Published As

Publication number Publication date
EP1298208B1 (en) 2006-03-15
IL112261A0 (en) 1995-03-30
CN1145638A (zh) 1997-03-19
NO962826D0 (no) 1996-07-04
EP0753062A1 (en) 1997-01-15
WO1995018854A1 (en) 1995-07-13
CN1267552C (zh) 2006-08-02
NO962826L (no) 1996-08-27
PT1298208E (pt) 2006-10-31
AU1391295A (en) 1995-08-01
JPH09508004A (ja) 1997-08-19
IL112261A (en) 2005-08-31
ES2260376T3 (es) 2006-11-01
NZ278432A (en) 1998-06-26
DE69534864T2 (de) 2007-02-22
DE69534864D1 (de) 2006-05-11
AU698730B2 (en) 1998-11-05
EP1298208A3 (en) 2004-01-07
EP0753062A4 (en) 1999-10-20
JP3691849B2 (ja) 2005-09-07
ATE320487T1 (de) 2006-04-15
CA2180358A1 (en) 1995-07-13
NO319376B1 (no) 2005-07-25
EP1298208A2 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
DK1298208T3 (da) Ribozymer der er målrettet mod en HIV-tat-sekvens
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
KR960703170A (ko) 안티센스 올리고뉴클레오티드 및 인간면역결핍바이러스감염에서 그것의 치료적이용(antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection)
WO1996019568A3 (en) Stabilized ribozyme analogs
CA2340416A1 (en) Co-lyophilized complex of a nucleic acid vector and a formulating agent
PT100472A (pt) Sequencias genomicas do virus da hepatite c e composicoes farmaceuticas que as contem, para diagnostico e terapeutica da hepatite c
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
WO1999029871A3 (fr) Sequences de circovirus associe a la maladie de l'amaigrissement du porcelet (map)
DE69634698D1 (de) Gewebespezifische und ziel-rna-spezifische ribozyme
DK1175489T3 (da) Oligonukleotider indeholdende en antisense-sekvens stabiliseret af en sekundær struktur og farmaceutiske præparater indeholdende disse oligonukleotider
CA2055612A1 (fr) Sequences oligonucleotidiques pour l'amplification du genome des retrovirus du type hiv-2 et siv, et leurs applications au diagnostic in-vitro des infections dues a ces virus
PT775745E (pt) Aptameros inibidores de catepsina g
DE69314911D1 (de) Cis-epoxide Derivate, verwendbar als irreversible HIV-Protease Inhibitoren und Verfahren und Zwischenprodukte zu ihrer Herstellung
DE69736002D1 (de) GEN ASSOZIIERT MIT IgA GLOMERULONEPHRITIS
DE69501081D1 (de) Oligonukleotide mit anti-cytomegalovirus wirkung
FR2771753B1 (fr) Gene de chitine-desacetylase, sequence d'adn hybridable, vecteur plasmidique qui le contient et organisme transforme par ce vecteur plasmidique
FR2701960B1 (fr) Polyribozyme apte à conférer, aux plantes, une résistance aux virus et plantes résistantes produisant ce polyribozyme.
ES2093554B1 (es) Procedimientos de amplificacion de genoma y mezclas de oligonucleotidos iniciadores para la deteccion y la identificacion de agentes infecciosos relacionados.
EP0596901A1 (en) CHIMERIC tRNA?LYS -RIBOZYME MOLECULES
Shah et al. Incorporation of an artificial protease and nuclease at the HIV-1 Tat binding site of trans-activation responsive RNA
SE9804298D0 (sv) New medical use
NO945020L (no) Selv-stabiliserende oligonukleotider som terapeutiske midler
RU93004565A (ru) N-цианопиридазиноны, способ их получения, гербицидное средство, способ его получения, способ борьбы с сорняками
TH23553EX (th) พาหะแสดงออกและการใช้พาหะเหล่านี้ในการเตรียมเซลของคนชนิดที่ต้านทาน hiv เพื่อใช้ในการบำบัดรักษา
TH7509EX (th) กระบวนการที่ใช้ในการรวมยีนที่เลือกสรรแล้วเข้าเป็นหน่วยเดียวกันกับโครโมโซมของแบคทีเรีย และแบคทีเรียที่ได้จากกระบวนการดังกล่าว